It will measure progression-free survival (PFS) as its primary endpoint ... with zilovertamab vedotin in patients with diffuse large B-cell lymphoma, compared to the current standard treatment.” ...

Matthew Matasar, MD, discussed what the findings from the ELM-1 trial of odronextamab in diffuse large B-cell lymphoma mean ...

and previous studies of the combination in relapsed or refractory DLBCL have demonstrated poor outcomes. Thus, the median PFS of placebo plus lenalidomide plus rituximab of only 2.6 months is not ...

Response assessments were completed in 37 patients with DLBCL and one with FL." The team tracked overall survival (OS) and progress-free survival (PFS) over 12 months, finding OS at 73.8% and PFS ...

Durations of response ranged from 63 to 644 days for patients with FL and from 34 to 685 days for patients with DLBCL. Patients with FL had a median PFS of 317 days (95% CI: 112–575) and ...

Managing R/R-transformed DLBCL remains a challenge, as affected patients have an approximate 27% chance of 4-year event-free survival and a 39% chance of overall survival. 2 Atezolizumab is a ...

About 30 percent of all non-Hodgkin lymphoma diagnoses in the United States are DLBCL. Although it is an aggressive cancer that can spread quickly, it is treatable. These can be symptoms of many ...

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid neoplasm. Three subtypes have been identified by gene-expression studies; germinal center (GC) DLBCL, non-GC DLBCL, and ...

These investigators used SEER data to compare the outcomes of transformed indolent non-Hodgkin lymphomas with de novo DLBCL at a population level, a situation for which little data exist.

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated diffuse large B-cell lymphoma ... free survival (PFS), with overall survival ...

ADCs in Preclinical Development for the Treatment of B-cell Malignancies With the evolving clinical data demonstrating the feasibility of the ADC platform in hematologic malignancies, the ...